Thomas Klima
Chief Operating Officer en BLUEBIRD BIO, INC. .
Fortuna: 159 795 $ al 31/03/2024
Perfil
Thomas J.
Klima is currently the Chief Operating & Commercial Officer at bluebird bio, Inc. He previously held positions as the Senior Director-Marketing at Dendreon Corp.
from 2009 to 2012, the Chief Commercial Officer & Senior Vice President at Navidea Biopharmaceuticals, Inc. from 2015 to 2017, and the Chief Commercial Officer at Gamida Cell Ltd.
from 2019 to 2020.
He obtained his undergraduate degree from Western State College of Colorado.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
BLUEBIRD BIO, INC.
0.06% | 04/03/2024 | 124 840 ( 0.06% ) | 159 795 $ | 31/03/2024 |
Cargos activos de Thomas Klima
| Empresas | Cargo | Inicio |
|---|---|---|
| BLUEBIRD BIO, INC. | Chief Operating Officer | 08/08/2022 |
Antiguos cargos conocidos de Thomas Klima.
| Empresas | Cargo | Fin |
|---|---|---|
| GAMIDA CELL LTD. | Corporate Officer/Principal | 01/12/2020 |
| NAVIDEA BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 08/03/2017 |
| DENDREON CORPORATION | Sales & Marketing | 01/09/2012 |
Formación de Thomas Klima.
| Western State College of Colorado | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Klima
